Aktuell ( Stand 2025 ) bernehmen gesetzliche Krankenkassen in Deutschland keine Abnehmmedikamente , auch keine Kombinationstherapien, wenn sie zur Gewichtsreduktion verschrieben werden
The figure below summarizes that, to date, the structures of eight different small molecule agonists have been resolved, all of which are located near the extracellular ligand-binding pocket compared to the GLP-1 peptide
*Correspondence: Juan S
GLP-1 has a variety of effects, originating from the presence of its receptors in specific nuclei of the lung, pancreas, gastrointestinal tract, kidney, heart, bone, central nervous system, etc
The FDA cannot verify the quality, safety, or effectiveness of these non-FDA-approved compounded GLP-1 products Entities engaged in mass marketing should be on notice. FDA Press Announcement In regulatory language, the agency also made clear that compounded products cannot be marketed as generic, clinically proven, or equivalent to approved drugs
(PubMed) Li S, Chen X, Li Q, et al